Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. - Wikidata - awgldk - TriplyDB

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

http://www.wikidata.org/entity/Q34481352

about

The HIV antiretroviral drug efavirenz has LSD-like properties Untangling the Gordian knot of HIV, stress, and cognitive impairment Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals Efavirenz and the CNS: what we already know and questions that need to be answered Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial Evolutionary dynamics of HIV at multiple spatial and temporal scales.Neurological and psychiatric adverse effects of antiretroviral drugs.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.HIV-associated neurocognitive disorders: perspective on management strategies Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.Etravirine in CSF is highly protein bound Antiretroviral bioanalysis methods of tissues and body biofluids.Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder.CSF penetration by antiretroviral drugs.Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Intranasal chitosan-g-HPβCD nanoparticles of efavirenz for the CNS targeting.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.[Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.CNS penetration of ART in HIV-infected children.Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.The Rise and Fall of Efavirenz.

P2860

Q24608183-0E26EC34-39BD-4C8E-8B18-06BB478201B3 Q28067483-C7DBA7BF-9B8D-4A0E-BC2A-266F7A15C078 Q28069383-CBDED3E8-0DA4-412D-AB87-AE556AC0C9A2 Q28085028-DBEDC959-56DA-4308-A2B9-7C90C572890A Q28486428-853CBA2A-614A-40E5-9E9D-E11F372C1449 Q28552729-58DA3655-357B-4625-B724-468D60BA42A7 Q30416280-A31C6485-FD15-4A56-B74C-EEA5BB5E2FE6 Q34039419-A056E555-C1E5-4DD2-8DE5-CB3CDCC1E070 Q34202181-13525763-D1D4-4F93-9054-CB71642CF3BD Q34652590-3885B885-90D0-4471-8534-68D8F50E6362 Q34756398-FA5FF62A-2A49-476D-A248-CD69A60EBAF7 Q36204440-DD1BE7A8-74A5-4C7D-9271-A11B3879D261 Q36374300-4F598770-408B-4A00-ADF4-4B52DD9EDA22 Q36406259-21746DD6-7CAF-4887-90E9-5C5D6870815A Q36573340-26730A68-BEA8-4E71-B544-1305CB9B76FC Q36664960-7D6F02A3-D142-4E52-B702-AAA53E31A1ED Q36667153-D728ABEA-ECAE-4135-981C-A42D105A88D5 Q36762988-09A2BCC5-EE86-42B1-8A31-242A4995DA7D Q37332868-08AE54A9-CA26-4C01-AE1D-FFC0EB307AFE Q37538717-02CDAE7C-6C12-4033-9582-AFFFE5A0BBD5 Q37966663-A79C3C5A-DE05-47B7-ACE8-DEA468E89192 Q38060571-2B10B61E-A961-40F9-BF3A-2691D86E14F2 Q38210096-0F291096-7894-41EE-BB0C-5F4DAC24CEF2 Q38247035-D2790376-029B-4F71-A188-C7F029C96FAC Q38706868-B6E4DBC0-09A7-482E-85CF-4AE76F2B2AA8 Q38990321-DF646344-D164-4D36-987B-30554EA475E4 Q39004638-B35C4463-98C6-41EF-B262-CD1185D230A6 Q39064765-78AF8142-D3F4-423A-BEDF-C2465F886C8D Q41033215-9CFC1A6E-5158-41F9-8002-2E3D4543937E Q41208022-4C5C0C40-215A-484E-B31A-FFFE31D0F6E0 Q41451997-D8071A76-9CB6-433F-858B-0B0958213F51 Q41602074-4AF5CB63-0570-48B3-9278-EE0E3454263C Q41748068-230E2C17-6CD2-4268-9EFB-AB1B1AC1A7CA Q42237457-8536A053-B687-4ED1-B1CF-F71D561A7DB5 Q42281323-B50D1C9A-F465-4202-AE04-E7E5A0C8E2FD Q42592784-A513A3EE-A22B-4299-891B-47382E37436D Q43419116-FC0158C8-62CB-46EE-91BE-823C441E2D0F Q47416079-39544C38-62D1-4CDC-81C4-56FE087D328D Q47817799-47DD5E77-5FE2-43E9-A2F0-59BCF1DF3B8C Q54665423-9869DA02-8E6A-401A-BEE2-928841AAC970

P2860

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

http://www.wikidata.org/entity/Q34481352

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@ast

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@en

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@nl

type

label

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@ast

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@en

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@nl

prefLabel

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@ast

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@en

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@nl

P1433

Q34481352-105DB1A3-0685-4137-8826-6786D1025710

P1476

Q34481352-5520A3ED-76A4-4186-8EFD-F2EBCCE35628

P2093

Q34481352-1DAAE6A1-BFDE-49F5-A9DB-DAF2D15FE78B

Q34481352-3A8C4B2E-3618-4E57-BCBA-1BF2B63A8E6E

Q34481352-40B79EEF-B494-4CB6-845A-A4D5CFE03443

Q34481352-6CEAD692-429B-46B4-A222-32075CC6635F

Q34481352-77D19B8A-1A00-4195-8A8D-7B69D555C4AF

Q34481352-79F73EE2-4FA2-4FDD-B862-1336584DE12F

Q34481352-8E960E19-C139-4D4E-8523-B05765046A88

Q34481352-9A88E359-0DD8-47B7-8C99-C2D0A3AFCBD9

Q34481352-CE656BC6-DCEF-4050-AE18-8AB0A8F755DF

Q34481352-CEC5DBF5-5A2E-426D-AC53-95C63DCB94F4

P2860

Q34481352-430507E0-E256-442B-9B53-6B156CC2153B

Q34481352-44ECF0EB-C43E-44FF-A600-1347BBA176DD

Q34481352-5D9F83A0-F0B4-493B-979F-0CC7F83895E9

Q34481352-68DFA999-DAE2-491B-8B24-AD61FB784890

Q34481352-70EFB09C-6ECB-4B47-9C3B-AB50138B4625

Q34481352-CCEED64B-6D2B-4190-A6B7-2A6F788BA202

Q34481352-DD465DFA-7713-4E41-BFAE-3C863A45EF13

P304

Q34481352-CB2F110B-DAB6-4A02-8E99-E9104E5E1956

P31

Q34481352-DA41AFBB-90FE-4C93-BF51-14A4E2A5361F

P356

Q34481352-DE1FDB28-AA00-4808-B38D-629AE9657F09

P407

Q34481352-B6AABE67-E552-4A5C-901B-705E297524FC

P433

Q34481352-463279A8-BEF7-4E9B-8D3C-802B59E79582

P478

Q34481352-4C7601A1-2988-47E7-AEE6-F8C05D0FE52F

P50

Q34481352-20D7D646-B11C-4E76-BB84-313A769CE67F

Q34481352-7FAFAFE2-20CA-43DC-8D08-2DE721A4B6F3

Q34481352-97B81C77-11BA-461C-A4EA-DD6B42C9CCE1

Q34481352-D865068C-4263-4B02-9433-EABD6B1526EC

P577

Q34481352-B42F2760-F90E-48F7-A817-55282CB20AA0

P5875

Q34481352-4006752C-9F45-4A69-BA80-52850243979F

P698

Q34481352-974D77BB-C06E-4341-BCC9-41A6D637598E

P932

Q34481352-A0DDB6B9-91DC-4EE3-B3E1-BE2404897023

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

@en

P2093

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Benjamin B Gelman

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

David M Simpson

http://www.w3.org/2001/XMLSchema#string

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

Gilbert Mbeo

http://www.w3.org/2001/XMLSchema#string

J Allen McCutchan

http://www.w3.org/2001/XMLSchema#string

Peter P Koopmans

http://www.w3.org/2001/XMLSchema#string

Richard Haubrich

http://www.w3.org/2001/XMLSchema#string

P2860

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients.

Cognitive dysfunction in HIV patients despite long-standing suppression of viremia

P304

354-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKQ434

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49629689

http://www.w3.org/2001/XMLSchema#string

P698

21098541

http://www.w3.org/2001/XMLSchema#string

P932

3019085

http://www.w3.org/2001/XMLSchema#string